giovedì 6 febbraio 2014

World Pharma News | Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation

World Pharma News | Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation

Nessun commento:

Posta un commento